Infertility
Inflammatory and structural reproductive dysfunction. MSC therapy supports endometrial repair, ovarian regeneration, and immune-mediated implantation failure.
Infertility — defined as failure to achieve pregnancy after 12 months of unprotected intercourse — affects approximately 10–15% of couples globally. In women, common etiologies include diminished ovarian reserve, polycystic ovarian syndrome, endometrial insufficiency (thin endometrium, Asherman's syndrome), recurrent implantation failure, and endometriosis.
Conventional treatment pathways — ovulation induction, IUI, and IVF — address the outcome (fertilization and implantation) but cannot repair the underlying endometrial or ovarian pathology that drives failure. Women with thin endometrium, premature ovarian insufficiency, or recurrent IVF failure have limited options within standard reproductive medicine.
MSC therapy is being explored for female infertility as a regenerative strategy targeting endometrial repair, ovarian reserve restoration, and immune-mediated implantation failure — conditions where the underlying biology is modifiable but not currently addressable by standard ART.
MSCs promote endometrial regeneration through two mechanisms: homing to damaged endometrial tissue and directly participating in glandular reconstruction, and secreting growth factors (VEGF, EGF, LIF) that stimulate resident endometrial stem cell proliferation, angiogenesis, and stromal regeneration. Pilot clinical studies have reported endometrial thickness increases and improved uterine blood flow following intrauterine MSC infusion in women with Asherman's syndrome and refractory thin endometrium.
For diminished ovarian reserve (DOR) and premature ovarian insufficiency (POI), MSC infusion has been observed to improve AMH levels, antral follicle count, and ovarian blood flow in published case series and small trials — likely through anti-apoptotic paracrine signaling to residual granulosa cells and primordial follicles.
True Regen coordinates reproductive history review, FSH, AMH, antral follicle count ultrasound, and hysteroscopy reports before designing a protocol. Each case is evaluated by Regen Cord's clinical team, and reproductive outcomes are tracked in collaboration with the patient's gynecologist or reproductive endocrinologist.
- Improved endometrial thickness and receptivity
- Increased AMH and antral follicle count in POI/DOR
- Better IVF implantation rate in recurrent failure cases
- Restoration of menstrual cycle in amenorrhea
- Improved pregnancy rate in treated patients
Individual results vary. All patients undergo full medical evaluation prior to treatment.
ISO/cGMP-Certified Lab
Every infusion is manufactured under pharmaceutical-grade controls. You receive a batch-specific Certificate of Analysis before treatment.
High-Dose MSC Protocol
Wharton's jelly umbilical-cord MSCs — younger, more potent, and more consistent than cells from the patient's own body.
Dedicated Coordinator
One person manages every detail of your journey — from your first inquiry through your 12-month follow-up.
Ready to take the next step?
One conversation could change everything.
Your dedicated coordinator will review your case and walk you through the entire process — with zero pressure, zero cost, and zero commitment.